IMNM vs. ALVO, MTSR, CPRX, VKTX, KYMR, CRNX, MLTX, MOR, IMVT, and HCM
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Alvotech (ALVO), Metsera (MTSR), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Immunovant (IMVT), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Immunome vs.
Immunome (NASDAQ:IMNM) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.
Immunome received 32 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 76.47% of users gave Immunome an outperform vote while only 50.00% of users gave Alvotech an outperform vote.
In the previous week, Alvotech had 11 more articles in the media than Immunome. MarketBeat recorded 23 mentions for Alvotech and 12 mentions for Immunome. Immunome's average media sentiment score of 1.25 beat Alvotech's score of 0.18 indicating that Immunome is being referred to more favorably in the media.
Immunome presently has a consensus price target of $23.33, suggesting a potential upside of 143.82%. Alvotech has a consensus price target of $18.00, suggesting a potential upside of 73.58%. Given Immunome's higher possible upside, equities research analysts clearly believe Immunome is more favorable than Alvotech.
Alvotech has a net margin of -123.47% compared to Immunome's net margin of -3,014.59%. Alvotech's return on equity of 0.00% beat Immunome's return on equity.
Immunome has higher earnings, but lower revenue than Alvotech. Immunome is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.
44.6% of Immunome shares are held by institutional investors. 8.6% of Immunome shares are held by company insiders. Comparatively, 0.5% of Alvotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Immunome has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.
Summary
Immunome beats Alvotech on 11 of the 17 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
This page (NASDAQ:IMNM) was last updated on 6/10/2025 by MarketBeat.com Staff
